Protagonist Therapeutics, Inc. (NASDAQ:PTGX) | WebDisclosure

Basculer en Français

10641	Companies
226256	Keywords
154740	Articles
119739	Press releases

Headlines Articles Press releases Protagonist Therapeutics, Inc.

Home
Companies
Protagonist Therapeutics, Inc.

PRESS RELEASE

published on 09/15/2025 at 16:45, 9 months 10 days ago

Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025
Protagonist Therapeutics to present Phase 2b ANTHEM-UC study data on targeted oral peptide icotrokinra at UEGW Week 2025 in Berlin. Company focuses on advanced therapies in ulcerative colitis

Ulcerative Colitis Protagonist Therapeutics Icotrokinra Phase 2b ANTHEM-UC Study UEGW Week 2025
BRIEF

published on 09/11/2025 at 14:05, 9 months 14 days ago

Un acteur majeur sollicite l'approbation de l'EMA pour l'icotrokinra dans le traitement du psoriasis

Essais Cliniques Icotrokinra Psoriasis En Plaques Efficacité Du Traitement Demande D'admission À L'EMA
BRIEF

published on 09/11/2025 at 14:05, 9 months 14 days ago

Protagonist Seeks EMA Approval for Icotrokinra in Psoriasis

Clinical Trials Plaque Psoriasis Icotrokinra Treatment Efficacy EMA Application
PRESS RELEASE

published on 09/11/2025 at 14:00, 9 months 14 days ago

Protagonist Announces Icotrokinra Application for Approval in Plaque Psoriasis Submitted to the European Medicines Agency
Protagonist Therapeutics submits application to EMA for first approval of icotrokinra, an investigational targeted oral peptide blocking IL-23 receptor in plaque psoriasis treatment

Protagonist Therapeutics Plaque Psoriasis Treatment IL-23 Receptor Icoktrokinra EMA Submission
BRIEF

published on 08/26/2025 at 22:10, 9 months 29 days ago

Protagonist Therapeutics Engages in Key Investment Conferences

Clinical Trials Protagonist Therapeutics Investment Conferences Biopharmaceutical Development Icotrokinra And Rusfertide
BRIEF

published on 08/26/2025 at 22:10, 9 months 29 days ago

Protagonist Therapeutics participe à des conférences d'investissement clés

Essais Cliniques Thérapeutique Protagoniste Conférences D'investissement Développement Biopharmaceutique Icotrokinra Et Rusfertide
PRESS RELEASE

published on 08/26/2025 at 22:05, 9 months 29 days ago

Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in September 2025
Protagonist Therapeutics announced CEO's participation in investment bank conferences in September. Company's advanced Phase 3 clinical development and future plans highlighted

Protagonist Therapeutics Phase 3 Clinical Development NDA Submission Investment Bank Conferences Drug Discovery Programs
BRIEF

published on 08/25/2025 at 13:05, 10 months ago

Le Rusfertide de Protagonist Therapeutics reçoit la désignation de thérapie révolutionnaire de la FDA

Rusfertide Thérapeutique Protagoniste Polyglobulie Vraie Thérapie Révolutionnaire Phase 3 VÉRIFIER
BRIEF

published on 08/25/2025 at 13:05, 10 months ago

Protagonist Therapeutics' Rusfertide Receives FDA Breakthrough Therapy Designation

Protagonist Therapeutics Rusfertide Polycythemia Vera Breakthrough Therapy Phase 3 VERIFY
PRESS RELEASE

published on 08/25/2025 at 13:00, 10 months ago

Rusfertide Receives Breakthrough Therapy Designation for Treatment of Erythrocytosis in Patients with Polycythemia Vera
Protagonist Therapeutics' rusfertide granted Breakthrough Therapy Designation by the FDA for polycythemia vera, complementing Orphan Drug and Fast Track designations. NDA filing on track for Q4

FDA Protagonist Therapeutics Rusfertide Breakthrough Therapy Designation NDA Filing

Accesswire

Published on 06/25/2026 at 15:30, 2 hours 48 minutes ago

Silver Spruce Resources, Inc. Adds Mining, Energy, and Finance Development Expertise to the Board and Announces Director Resignation
Published on 06/25/2026 at 15:00, 3 hours 18 minutes ago

Jaguar Health Announces Conversion of Series O Convertible Preferred Stock Issued as Recent One-time Stock Dividend
Published on 06/25/2026 at 14:30, 3 hours 48 minutes ago

Unusual Machines Expands Orlando Manufacturing Footprint to Support Battery Operations
Published on 06/25/2026 at 14:01, 4 hours 17 minutes ago

Worksport (NASDAQ:WKSP) Regains $1 Bid Price Requirement, Announces CEO Town Hall, Highlights Multiple Recent Growth Drivers in CEO Letter
Published on 06/25/2026 at 14:00, 4 hours 18 minutes ago

Horizon Aircraft's Leadership Team to Participate at Farnborough International Airshow 2026

View all ACCESSWIRE

EQS Group

Published on 06/25/2026 at 18:00, 18 minutes ago

EUROPLASMA: Projet de cession des activités de défense : poursuite des discussions
Published on 06/25/2026 at 17:45, 33 minutes ago

REALITE annonce un nouveau report de la publication de ses résultats annuels 2025 et ajuste en conséquence le calendrier de ses opérations de conversion de créances en capital
Published on 06/25/2026 at 17:30, 48 minutes ago

TFREE Formally Launches at EUROBIKE 2026: Architecting the Operating System for AI Micro Mobility
Published on 06/25/2026 at 17:08, 1 hour 10 minutes ago

Grand City Properties S.A. announces dividend of EUR 0.30 per share
Published on 06/25/2026 at 17:07, 1 hour 11 minutes ago

Grand City Properties S.A. announces dividend of EUR 0.30 per share

Les Echos

Published on 06/25/2026 at 17:50, 28 minutes ago

DISCLOSURE OF SHARE CAPITAL AND VOTING RIGHTS
Published on 06/25/2026 at 17:50, 28 minutes ago

DECLARATION D’ACTIONS ET DE DROITS DE VOTE
Published on 06/25/2026 at 15:58, 2 hours 20 minutes ago

260625 BENETEAU Transactions sur actions propres
Published on 06/25/2026 at 07:30, 10 hours 48 minutes ago

Gimv signs an agreement to acquire Groupe Cap Vert, France’s leading multi-specialist provider of tree and vegetation critical management services, from Ambienta.
Published on 06/25/2026 at 07:30, 10 hours 48 minutes ago

Gimv ondertekent een overeenkomst voor de overname van Groupe Cap Vert, de Franse marktleider in multispecialistische essentiële diensten voor het beheer van bomen en groene infrastructuur, van Ambienta.

View all LES ECHOS COMFI WIRE